BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 28919620)

  • 1. Role of Serum Pepsinogen I and II Ratio in Screening of Gastric Carcinoma.
    Begum A; Baten MA; Begum Z; Ahsan MM; Rahman SF; Chowdhury F; Khan AH
    Mymensingh Med J; 2017 Jul; 26(3):628-634. PubMed ID: 28919620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum pepsinogen I and II levels in various gastric disorders with special reference to their use as a screening test for carcinoma stomach.
    Parthasarathy G; Maroju NK; Kate V; Ananthakrishnan N; Sridhar MG
    Trop Gastroenterol; 2007; 28(4):166-70. PubMed ID: 18416347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Studies on the cut-off value of serum pepsinogen abnormality for screening chronic atrophic gastritis and gastric carcinoma].
    Li YH; Zhang XH; Huang B; Wang JL; Mi JM; Shen HT; Zhang ZG; Yan X; Xing LX; Wang SJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2006 Oct; 27(10):840-4. PubMed ID: 17343174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastric cancer screening using the serum pepsinogen test method.
    Miki K
    Gastric Cancer; 2006; 9(4):245-53. PubMed ID: 17235625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening.
    Dinis-Ribeiro M; Yamaki G; Miki K; Costa-Pereira A; Matsukawa M; Kurihara M
    J Med Screen; 2004; 11(3):141-7. PubMed ID: 15333273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of serum pepsinogen I , II and osteopontin co-detection in gastric cancer screening].
    Gong YH; Sun LP; Yuan Y
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):691-3. PubMed ID: 17274377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum pepsinogen I, pepsinogen II, and gastrin 17 in relatives of gastric cancer patients: comparative study with type and severity of gastritis.
    Haj-Sheykholeslami A; Rakhshani N; Amirzargar A; Rafiee R; Shahidi SM; Nikbin B; Khosravi F; Massarrat S
    Clin Gastroenterol Hepatol; 2008 Feb; 6(2):174-9. PubMed ID: 18237867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic value of serum pepsinogen I, pepsinogen II, and gastrin-17 levels for population-based screening for early-stage gastric cancer.
    Wang Y; Zhu Z; Liu Z; Zhao Z; Xue X; Li X; Li P; Rong G; Ma Y
    J Int Med Res; 2020 Mar; 48(3):300060520914826. PubMed ID: 32228342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Correlation of serum pepsinogen level and gastric mucosal changes of residents in the high incidence area of gastric cancer].
    Zhang XH; Huang B; Wang JL; Li YH; Mi JM; Shen HT; Zhang ZG; Yan X; Xing LX; Wang SJ
    Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):507-11. PubMed ID: 17147114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Helicobacter pylori infection in combination with the serum pepsinogen I/II ratio and interleukin-1beta-511 polymorphisms are independent risk factors for gastric cancer in Thais.
    Yamada S; Matsuhisa T; Makonkawkeyoon L; Chaidatch S; Kato S; Matsukura N
    J Gastroenterol; 2006 Dec; 41(12):1169-77. PubMed ID: 17287896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Detection of gastric preneoplastic lesions with serum levels of pepsinogen in Chilean subjects].
    Fernández F JI; de Aretxabala U X; Santander D R; Sabah T S; Maira S J; Navarro R A; Planzer D M; Gómez L F; Etchart M; Gallegos I; Torrens X; Fasce P G; Reydet I
    Rev Med Chil; 2007 Dec; 135(12):1519-25. PubMed ID: 18357351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of serum pepsinogen levels for the diagnosis of gastric diseases in Chinese Han people in midsouth China.
    Zhang XM; Li JX; Zhang GY; Li XH; Gu H
    BMC Gastroenterol; 2014 Jan; 14():3. PubMed ID: 24383519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-parietal cell antibody and serum pepsinogen assessment in screening for gastric carcinoma.
    Sugiu K; Kamada T; Ito M; Kaya S; Tanaka A; Kusunoki H; Hata J; Haruma K
    Dig Liver Dis; 2006 May; 38(5):303-7. PubMed ID: 16549394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal cutoff value of the serum pepsinogen level for prediction of gastric cancer incidence: the Hisayama Study.
    Shikata K; Ninomiya T; Yonemoto K; Ikeda F; Hata J; Doi Y; Fukuhara M; Matsumoto T; Iida M; Kitazono T; Kiyohara Y
    Scand J Gastroenterol; 2012 Jun; 47(6):669-75. PubMed ID: 22428879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance in combined detection of serum pepsinogen I, pepsinogen II and carbohydrate antigen 242 in gastric cancer.
    Yun L; Bin Z; Guangqi G; Ding L; Xingdang L; Biao H
    Hepatogastroenterology; 2014; 61(129):255-8. PubMed ID: 24895832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The optimal serum pepsinogen cut-off value for predicting histologically confirmed atrophic gastritis.
    Kim EH; Kang H; Park CH; Choi HS; Jung DH; Chung H; Park JC; Shin SK; Lee SK; Lee YC
    Dig Liver Dis; 2015 Aug; 47(8):663-8. PubMed ID: 26077884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accuracy of screening for gastric cancer using serum pepsinogen concentrations.
    Kitahara F; Kobayashi K; Sato T; Kojima Y; Araki T; Fujino MA
    Gut; 1999 May; 44(5):693-7. PubMed ID: 10205207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serological assessment of gastric intestinal metaplasia and atrophy using pepsinogen-I, pepsinogen-II and gastrin-17 levels in a low incidence area of gastric cancer endemic for H. pylori infection.
    Ghoshal UC; Kumar S; Krishnani N; Kumari N; Chourasia D; Tripathi S
    Trop Gastroenterol; 2011; 32(4):292-8. PubMed ID: 22696910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum pepsinogen test for early detection of gastric cancer in a European country.
    Lomba-Viana R; Dinis-Ribeiro M; Fonseca F; Vieira AS; Bento MJ; Lomba-Viana H
    Eur J Gastroenterol Hepatol; 2012 Jan; 24(1):37-41. PubMed ID: 21989121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a high risk gastric cancer group using serum pepsinogen after successful eradication of Helicobacter pylori.
    Haneda M; Kato M; Ishigaki S; Suzuki M; Takahashi M; Nakagawa M; Ono S; Mori Y; Mabe K; Nakagawa S; Kudo T; Shimizu Y; Asaka M
    J Gastroenterol Hepatol; 2013 Jan; 28(1):78-83. PubMed ID: 23034090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.